2025
Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review
Jacobs J, Binns T, Schlafer D, Woo J, Booth G, Adkins B. Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review. Transfusion And Apheresis Science 2025, 64: 104081. PMID: 39883995, DOI: 10.1016/j.transci.2025.104081.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraSecondary thrombotic thrombocytopenic purpuraFood and Drug Administration Adverse Event Reporting SystemAssociated with alemtuzumabThrombocytopenic purpuraMultiple sclerosisReport of thrombotic thrombocytopenic purpuraImmune-mediated thrombotic thrombocytopenic purpuraCongenital thrombotic thrombocytopenic purpuraHematopoietic stem cell transplantationFAERS databaseAnd Drug Administration Adverse Event Reporting SystemStem cell transplantationUnited States Food and Drug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemADAMTS13 deficiencyAlemtuzumab administrationCell transplantationADAMTS13 geneEvent Reporting SystemPatient demographicsAlemtuzumabCase reportTherapy indicationsCross-sectional analysis
2024
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic
Friedman J, Sheeder J, Polotsky A, Lazorwitz A. Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic. Obstetrical & Gynecological Survey 2024, 79: 643-644. DOI: 10.1097/01.ogx.0001095056.57063.30.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraFamily planning clinicsReproductive-age womenHerbal supplementsOral contraceptivesThrombocytopenic purpuraAdverse eventsPlanning clinicsDrug interactionsSupplement useCardiac arrhythmiasHerbal supplement useDepression medicationPrescription medicationsDrugGastrointestinal illnessMedicationRisk associated with interactionsSupplementationPurpuraContraceptionArrhythmiasThe seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs J, Stanek C, Booth G, Symeonidis A, Shih A, Allen E, Gavriilaki E, Grossman B, Pavenski K, Moorehead A, Peyvandi F, Agosti P, Mancini I, Stephens L, Raval J, Mingot‐Castellano M, Crowe E, Daou L, Pai M, Arnold D, Marques M, Henrie R, Smith T, Sreenivasan G, Siniard R, Wallace L, Yamada C, Duque M, Wu Y, Harrington T, Byrnes D, Bitsani A, Davis A, Robinson D, Eichbaum Q, Villalba C, Juskewitch J, Kaiafa G, Kapsali E, Klapper E, Perez‐Alvarez I, Klein M, Kotsiou N, Lalayanni C, Mandala E, Aldarweesh F, Alkhateb R, Fortuny L, Mellios Z, Papalexandri A, Parsons M, Schlueter A, Tormey C, Wellard C, Wood E, Jia S, Wheeler A, Powers A, Webb C, Yates S, Bouzid R, Coppo P, Bloch E, Adkins B. The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes. American Journal Of Hematology 2024, 99: 2063-2074. PMID: 39136282, DOI: 10.1002/ajh.27458.Peer-Reviewed Original ResearchCost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategies
2023
Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Cuker A, Goshua G. Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura. Blood 2023, 142: 368. DOI: 10.1182/blood-2023-184927.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraTherapeutic plasma exchangeIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraPLASMIC scoreIncremental net monetary benefitProbabilistic sensitivity analysesPlasma exchangeThrombocytopenic purpuraMedical intensive care unitADAMTS13 activity testingIntensive care unitCare of patientsActivity levelsHigh pretest probabilityClinical trial dataCost-effectiveness ratioCost-effectiveness evaluationDeterministic sensitivity analysesNet monetary benefitEmpiric treatmentAdverse eventsPrimary outcomeIll adultsCare unitThrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings — Connecticut, July 2022
Hogeland E, Somers T, Yip L, Doyon S, Redlich C, Orsey A, Woda C, Swan S, Feder H. Thrombocytopenia Associated with Elemental Mercury Poisoning in Two Siblings — Connecticut, July 2022. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1027-1031. PMID: 37733629, PMCID: PMC10519713, DOI: 10.15585/mmwr.mm7238a2.Peer-Reviewed Original ResearchConceptsIntravenous immune globulinSevere thrombocytopeniaElemental mercury poisoningImmune thrombocytopenic purpuraThrombopoietin receptor agonistsPossible infectious causesElemental mercury toxicityPublic health outreachPetechial rashOral mucositisImmune globulinProlonged hospitalizationInfectious causesPlatelet transfusionsThrombocytopenic purpuraThrombocytopenia AssociatedReceptor agonistHealth outreachPoison controlEarly detectionToxic exposureMercury exposureEnvironmental exposuresMercury poisoningDimercaptosuccinic acidGlobal Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP)
Butt A, Allen C, Purcell A, Ito S, Goshua G. Global Health Resource Utilization and Cost-Effectiveness of Therapeutics and Diagnostics in Immune Thrombotic Thrombocytopenic Purpura (TTP). Journal Of Clinical Medicine 2023, 12: 4887. PMID: 37568288, PMCID: PMC10420213, DOI: 10.3390/jcm12154887.Peer-Reviewed Original Research
2022
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?
Goshua G, Bendapudi P. Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura? Hematology 2022, 2022: 491-494. PMID: 36485149, PMCID: PMC9820987, DOI: 10.1182/hematology.2022000412.Peer-Reviewed Original ResearchPresentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease
Casasanta N, Shah N, Troy K, Edwards C, Patel R. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease. Blood Coagulation & Fibrinolysis 2022, 33: 422-424. PMID: 35867945, DOI: 10.1097/mbc.0000000000001154.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraThrombocytopenic purpuraGraves' diseaseAutoimmune diseasesConcurrent thrombotic thrombocytopenic purpuraDeficient activity of ADAMTS13Retrospective review of patientsDiagnosing TTPUncontrolled autoimmune diseaseReview of patientsThyroid function testsAutoimmune thyroid diseaseActivity of ADAMTS13Thrombotic microangiopathyRetrospective reviewThyroid diseaseAutoimmune disordersStandard treatmentFunction testsDeficient activityPatientsThyrotoxicosisPurpuraDiseaseGraves
2020
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2020, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agentsCost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraQuality-adjusted life yearsIntensive care unitTherapeutic plasma exchangeHERCULES trialCost-effectiveness analysisCaplacizumab treatmentRituximab useTITAN trialHospital lengthTPE sessionsThrombocytopenic purpuraTreatment armsAcquired Thrombotic Thrombocytopenic PurpuraLong-term disease courseThrombotic microangiopathy leadingEnd-organ damagePlatelet count recoveryLong-term followHealth system perspectiveOne-way sensitivity analysesPotential confounding factorsCost-effectiveness ratioLife-threatening diseaseCost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSettingSpontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP state
Browning S, Bahar B, Lee AI, Gorshein E. Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a ‘subclinical’ TTP state. Hematology 2020, 25: 473-477. PMID: 33269995, DOI: 10.1080/16078454.2020.1848973.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraMicroangiopathic haemolytic anaemiaADAMTS13 activity levelsPlasma exchangeHaemolytic anaemiaThrombocytopenic purpuraHaematologic parametersSpontaneous recoveryAcute thrombotic thrombocytopenic purpuraMild haemolytic anaemiaUrgent plasma exchangeInitiation of therapyHereditary thrombotic thrombocytopenic purpuraActivity levelsDeficiency of ADAMTS13High mortality rateClinical remissionDisease remissionThrombotic microangiopathyPrompt treatmentThrombotic manifestationsADAMTS13 inhibitorUrgent therapyAsymptomatic femalesClinical manifestations
2019
P3603Impact of idiopathic thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction
Chehab O, Pahuja M, Adegbala O, Akintoye E, Ramia P, Morsi R, Alrojolah L, Mishra T, Shokr M, Kanj A, Abdallah N, Tabaja H, Afonso L, Abidov A. P3603Impact of idiopathic thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction. European Heart Journal 2019, 40: ehz745.0462. DOI: 10.1093/eurheartj/ehz745.0462.Peer-Reviewed Original ResearchIdiopathic thrombocytopenic purpuraAcute myocardial infarctionLength of stayLonger LOSNon-ITP patientsAcute ischemic strokeClinical outcomesHospital mortalitySecondary outcomesThrombocytopenic purpuraAMI patientsMyocardial infarctionACC/AHA/ESCUS National Inpatient Sample databaseNational Inpatient Sample databaseCardiovascular risk factorsPropensity-matched cohortLow platelet countManagement of patientsShort-term mortalityLong-term outcomesCoronary revascularization proceduresHospital complicationsMore comorbiditiesAnticoagulation therapyThe color of skin: purple diseases of the skin, nails, and mucosa
Steuer AB, Cohen JM. The color of skin: purple diseases of the skin, nails, and mucosa. Clinics In Dermatology 2019, 37: 528-547. PMID: 31896408, DOI: 10.1016/j.clindermatol.2019.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsAntiphospholipid SyndromeCalciphylaxisChurg-Strauss SyndromeColorCryoglobulinemiaDiagnosis, DifferentialGranulomatosis with PolyangiitisHumansLevamisoleMicroscopic PolyangiitisNecrosisPolyarteritis NodosaPurpura FulminansPurpura, Thrombotic ThrombocytopenicSkinVasculitisWarfarinConceptsCutaneous vasculitisCutaneous small vessel vasculitisLevamisole-induced vasculopathyAntiphospholipid antibody syndromeSmall vessel vasculitisThrombotic thrombocytopenic purpuraAntibody syndromeEosinophilic granulomatosisPolyarteritis nodosumEcthyma gangrenosumMicroscopic polyangiitisSkin necrosisInfectious dermatosesLichen planusPurpura fulminansThrombocytopenic purpuraInflammatory dermatosesSystemic diseaseClinical appearanceKaposi's sarcomaVasculitisPolyangiitisGranulomatosisVasculopathyDermatosesBleeding Scales Applicable to Critically Ill Children: A Systematic Review.
Nellis ME, Levasseur J, Stribling J, Faustino EVS, Zantek ND, Sheth S, Karam O. Bleeding Scales Applicable to Critically Ill Children: A Systematic Review. Pediatric Critical Care Medicine 2019, 20: 603-607. PMID: 30925573, DOI: 10.1097/pcc.0000000000001943.Peer-Reviewed Original ResearchConceptsIll childrenIdiopathic thrombocytopenic purpuraFull-text articlesBleeding scoreBleeding scaleClinical outcomesIll patientsThrombocytopenic purpuraOvid EmbaseCochrane LibraryDatabase inceptionOvid MEDLINEElectronic searchUnique citationsSystematic reviewFinal reviewClinical measurementsOutpatientsInpatientsChildrenAdultsOutcomesBleedingPurpuraHemorrhageThrombotic thrombocytopenic purpura (TTP) presenting with severe neurological manifestations in a patient with well-controlled HIV-1 (P4.9-010)
Kimbrough T, Sanmartin P, Litvinov B, Navaratnam D. Thrombotic thrombocytopenic purpura (TTP) presenting with severe neurological manifestations in a patient with well-controlled HIV-1 (P4.9-010). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p4.9-010.Peer-Reviewed Original Research
2017
Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States
Giri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. Blood 2017, 130: 675. DOI: 10.1182/blood.v130.suppl_1.675.675.Peer-Reviewed Original ResearchThrombotic thrombocytopenic purpuraHospital volumeInpatient mortality rateNationwide Inpatient SampleInpatient mortalityThrombocytopenic purpuraPotential confoundersMortality rateOverall inpatient mortality rateInitiation of plasmapheresisUnique hospital identifiersHigher inpatient mortalityRetrospective cohort studyHigh-volume hospitalsAdjusted odds ratioLogistic regression analysisHierarchical logistic regression analysisTest of trendUnique hospitalizationsHospital mortalityInpatient outcomesHospital courseTotal hospitalizationsVolume hospitalsAdult patients
2016
Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma
Sidhu D, Snyder EL, Tormey CA. Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma. Journal Of Clinical Apheresis 2016, 32: 158-162. PMID: 27246502, DOI: 10.1002/jca.21475.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeThrombotic thrombocytopenic purpuraSevere allergic reactionsAnaphylactic reactionsTTP exacerbationTTP remissionTreatment strategiesAllergic reactionsVon Willebrand factor (VWF) cleaving proteasePotential treatment strategyPossible treatment protocolReplacement plasmaAdverse eventsAcute treatmentPlasma exchangeThrombocytopenic purpuraSimilar patientsClinical dilemmaTreatment protocolAllergic riskPatientsDonor plasmaADAMTS-13Plasma productsStandard plasma
2015
Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion
Sullivan H, Arthur C, Patel S, Hendrickson J, Lazarus A, Stowell S. Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion. Blood 2015, 126: 3570. DOI: 10.1182/blood.v126.23.3570.3570.Peer-Reviewed Original ResearchDirect antiglobulin testAutoimmune hemolytic anemiaRed blood cellsAntigen lossAntigen levelsRhD antigenHemolytic anemiaPost-infusion samplesTarget antigenAntigen detectionRhD-positive red blood cellsK antigenIncompatible RBC transfusionIdiopathic thrombocytopenic purpuraAnti-RhD antibodiesHospital blood bankSignificant complement activationImmune globulinRBC transfusionThrombocytopenic purpuraAntiglobulin testMurine modelAntibody injectionRBC clearanceDetectable antigen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply